Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Functional precision medicine is a strategy whereby live tumor cells from affected individuals
are directly perturbed with drugs to provide immediately translatable, personalized …

Combination chemotherapy can cure certain leukemias and lymphomas, but most solid
cancers are only curable at early stages. We review quantitative principles that explain the …

Prognostically relevant RNA expression states exist in pancreatic ductal adenocarcinoma
(PDAC), but our understanding of their drivers, stability, and relationship to therapeutic …

Combinatorial therapies that target multiple pathways have shown great promises for
treating complex diseases. DrugComb (https://drugcomb. org/) is a web-based portal for the …

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents
the most common subtype of lymphoma. Although 60–70% of all patients can be cured by …

Purpose: Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies
have been approved for advanced cancers in multiple indications, and numerous trials are …

Background It is highly desirable to develop new therapeutic strategies for gastric cancer
given the low survival rate despite improvement in the past decades. Cadherin 17 (CDH17) …

Most targeted anticancer therapies fail due to drug resistance evolution. Here we show that
tumor evolution can be reproducibly redirected to engineer therapeutic opportunity …

DLBCL is the most common lymphoma with high tumor heterogeneity. Treatment
refractoriness and relapse from R-CHOP therapy in patients remain a clinical problem …